Trial · NCT01693653
Tocilizumab for the Treatment of Behcet's Syndrome
NCT01693653, Phase 2, Terminated, NYU Langone Health; results first posted 2016-06-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tocilizumab for the Treatment of Behcet's Syndrome. Trials, record NCT01693653. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01693653
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tocilizumab for the Treatment of Behcet's Syndrome
- NCT number
- NCT01693653
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- NYU Langone Health
- Conditions
- Behcet Syndrome
- Interventions
- Tocilizumab
- First posted
- 2012-09-26
- Last updated
- 2019-02-15
- Results first posted
- 2016-06-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Primary Outcome | 9 months | The study was terminated. No data were collected for this Outcome Measure. |
| Secondary | Genital Ulcers | 9 months | The study was terminated. No data were collected for this outcome measure. |
| Secondary | Oral Ulcers | 9 months | The study was terminated. No data were collected for this outcome measure. |
| Secondary | Treatment Failures | 9 months | The study was terminated. No data were collected for this outcome measure. |
| Secondary | Oral Ulcer Pain | 9 months | The study was terminated. No data were collected for this outcome measure. |
| Secondary | Gential Ulcer Pain | 9 months | The study was terminated. No data were collected for this outcome measure. |
| Secondary | BSAS | 9 months | The study was terminated. No data were collected for this outcome measure. |
| Secondary | MDHAQ | 9 months | The study was terminated. No data were collected for this outcome measure. |
| Secondary | BDCAF | 9 months | The study was terminated. No data were collected for this outcome measure. |
| Secondary | Safety | 9 moths | The study was terminated. No data were collected for this outcome measure. |
Source ClinicalTrials.gov
Outcomes10
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Primary Outcome | 9 months | The study was terminated. No data were collected for this Outcome Measure. | ||
| SECONDARY | Genital Ulcers | 9 months | Terminated due to low enrollments. Data for 1 subject not analyzed. | ||
| SECONDARY | Oral Ulcers | 9 months | Terminated due to low enrollments. Data for 1 subject not analyzed. | ||
| SECONDARY | Treatment Failures | 9 months | Terminated due to low enrollments. Data for 1 subject not analyzed. | ||
| SECONDARY | Oral Ulcer Pain | 9 months | Terminated due to low enrollments. Data for 1 subject not analyzed. | ||
| SECONDARY | Gential Ulcer Pain | 9 months | Terminated due to low enrollments. Data for 1 subject not analyzed. | ||
| SECONDARY | BSAS | 9 months | Terminated due to low enrollments. Data for 1 subject not analyzed. | ||
| SECONDARY | MDHAQ | 9 months | Terminated due to low enrollments. Data for 1 subject not analyzed. | ||
| SECONDARY | BDCAF | 9 months | Terminated due to low enrollments. Data for 1 subject not analyzed. | ||
| SECONDARY | Safety | 9 moths | Terminated due to low enrollments. Data for 1 subject not analyzed. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Tocilizumab | 1 | |
| Overall Study | STARTED | Placebo | 0 | |
| Overall Study | COMPLETED | Tocilizumab | 1 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Tocilizumab | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Tocilizumab | 0 | 1 |
| Total, all-cause mortality | Placebo | 0 | 0 |
| Total, other adverse events | Tocilizumab | 0 | 1 |
| Total, other adverse events | Placebo | 0 | 0 |
| Total, serious adverse events | Tocilizumab | 0 | 1 |
| Total, serious adverse events | Placebo | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01693653
GET https://conductscience.org/api/trials/v1/NCT01693653/registered